Q3 2024 · 13F-HR
Propel Bio Management, LLCholdings as filed
Filed 2024-11-13 · accession 0001829126-24-007453
$172.4M
Reported value
21
Positions
2024-09-30
Period end
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 03828A101 | APLT | APPLIED THERAPEUTICS INC | $55.8M | 32.4% | 6,567,858 | Common | SOLE |
| 72651A207 | PAGP | PLAINS GP HOLDINGS LP-CL | $23.5M | 13.7% | 1,272,360 | Common | SHARED |
| 71722W107 | PHAT | PHATHOM PHARMACEUTICALS I | $15.7M | 9.12% | 869,927 | Common | SHARED |
| 004468500 | ACHV | ACHIEVE LIFE SCIENCES INC | $11.6M | 6.74% | 2,453,092 | Common | SOLE |
| 89854M101 | TCRX | TSCAN THERAPEUTICS INC | $10.4M | 6.03% | 2,087,139 | Common | SHARED |
| 00973Y108 | AKRO | AKERO THERAPEUTICS INC | $9.9M | 5.72% | 343,729 | Common | SHARED |
| 558868105 | MDGL | MADRIGAL PHARMACEUTICALS | $9.1M | 5.30% | 43,032 | Common | SHARED |
| 05370A108 | RNAGBP | AVIDITY BIOSCIENCES INC | $8.2M | 4.76% | 178,500 | Common | SHARED |
| 039697107 | ARDX | ARDELYX INC | $7.4M | 4.28% | 1,070,947 | Common | SHARED |
| 879512309 | TSAT | TELESAT CORP | $4.8M | 2.79% | 365,781 | Common | SHARED |
| 00289Y206 | ABEO | ABEONA THERAPEUTICS INC | $3.9M | 2.29% | 624,022 | Common | SHARED |
| 501575104 | KYMR | KYMERA THERAPEUTICS INC | $2.7M | 1.55% | 56,359 | Common | SHARED |
| 87164F105 | SNDX | SYNDAX PHARMACEUTICALS IN | $2.6M | 1.49% | 133,259 | Common | SHARED |
| 50127T109 | KURA | KURA ONCOLOGY INC | $2.5M | 1.47% | 130,000 | Common | SHARED |
| 488445206 | ZVRA | ZEVRA THERAPEUTICS INC | $1.2M | 0.72% | 179,874 | Common | SHARED |
| 28249U204 | 72C | EIGER BIOPHARMACEUTICALS | $1.2M | 0.72% | 146,381 | Common | SHARED |
| 04746L104 | — | ATHIRA PHARMA INC | $665,785 | 0.39% | 1,492,792 | Common | SHARED |
| 20451W101 | CMPS | COMPASS PATHWAYS LTD | $504,000 | 0.29% | 80,000 | Common | SOLE |
| 92511W108 | — | VERRICA PHARMACEUTICALS I | $500,159 | 0.29% | 344,937 | Common | SHARED |
| F5888J116 | MATPF | MAAT PHARMA SACA | $17,786 | 0.01% | 2,397 | Common | SHARED |
| 169CVR016 | — | CHINOOK THERAPEUTICS | $9,750 | 0.01% | 79,357 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.